Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis
Over the past 10 years, Vertex Pharmaceuticals (VRTX) earnings per share (EPS) grew 76.6% a year, revenue grew 27.9% a year and free cash flow grew 87.8% a year, with an average return on invested capital (ROIC) of 10.6%. VRTX stock trades at $499.74, a P/E of 28.9, above its historical average of 27.1. Analysts' average 12-month price target is $573.50 (+14.8%).
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF).
Exhibit A Growth Dossier
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S | 33.9% | 17.0% | 19.4% | A+ |
| EPS GrowthEPS | 76.6% | 8.2% | 10.5% | A- |
| Revenue GrowthRevenue | 27.9% | 14.2% | 10.6% | A |
| Cash Flow GrowthCash Flow | 87.8% | 1.3% | 8.5% | A- |
| ROICROIC | 10.6% | 16.0% | 18.1% | A- |
Exhibit B Valuation Ledger
- Current EPS
- $17.32
- Historical Avg P/E
- 27.1
- Future P/E (used for sticker price)
- Projected EPS (10yr)
- Sticker Price (10yr)
- Price for 15% Annual Return
- Expected Annual Return
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
Exhibit C Raw Data (last 10 years)
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | $3.90 | $4.73 | $8.01 | $17.11 | $23.34 | $32.98 | $38.86 | $53.70 | $67.49 | $63.63 | $72.35 | $79.19 | |
| Basic EPSEPS | -$2.32 | -$0.46 | $1.06 | $8.25 | $4.58 | $10.44 | $9.09 | $12.97 | $14.05 | -$2.08 | $15.46 | $17.32 | |
| RevenueRevenue | $1,032,336,000 | $1,702,177,000 | $2,488,652,000 | $3,047,597,000 | $4,162,821,000 | $6,205,683,000 | $7,574,400,000 | $8,930,700,000 | $9,869,200,000 | $11,020,100,000 | $12,074,600,000 | $12,624,300,000 | |
| Free Cash FlowCash Flow | $-410,734,000 | $179,540,000 | $585,521,000 | $1,174,762,000 | $1,493,879,000 | $2,993,705,000 | $2,408,500,000 | $3,925,200,000 | $3,278,900,000 | $-790,300,000 | $3,193,800,000 | $3,796,100,000 | |
| ROIC (%)ROIC | -22.5% | 0.4% | -26.1% | 12.4% | 14.4% | 25.1% | 21.0% | 21.8% | 16.4% | 2.6% | 18.1% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Ticker INVESTigator Price Target
Analyst Data
Price Target
Where the stock trades today vs. the range of 12-month price targets from covering analysts.
56 firms rate it — 48 buy, 7 hold, 1 sell · Most recent Oct 2026
VRTX Stock FAQ
What is VRTX's stock price target?
The average 12-month analyst price target for VRTX is $573.50, with a range of $350.00 to $665.00. That is +14.8% from the current price of $499.74.
Do analysts rate VRTX a buy?
Most rate it a buy. Of 56 firms covering Vertex Pharmaceuticals, the ratings are 48 buy or strong buy, 7 hold and 1 sell or strong sell.
How fast is Vertex Pharmaceuticals growing?
Annual growth rates for VRTX. EPS: 76.6% over 10 years, 8.2% over 5 years, 10.5% over 1 year. Revenue: 27.9% over 10 years, 14.2% over 5 years, 10.6% over 1 year. Free cash flow: 87.8% over 10 years, 1.3% over 5 years, 8.5% over 1 year. Book value per share: 33.9% over 10 years, 17.0% over 5 years, 19.4% over 1 year.
What is VRTX's ROIC?
Vertex Pharmaceuticals' return on invested capital (ROIC) was 18.1% in fiscal 2025. Its 10-year average ROIC is 10.6%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
What is VRTX's P/E ratio?
VRTX's current P/E ratio is 28.9, compared with a historical average of 27.1. Trailing earnings per share are $17.32.
What is Vertex Pharmaceuticals' market cap and stock price?
VRTX last traded at $499.74 as of October 19, 2026. Its 52-week range is $403.16 to $560.25. Vertex Pharmaceuticals has a market cap of $126.66B.
Exhibit D Related Coverage
Similar Stocks
Data as of October 19, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.